Pharming Group (NASDAQ:PHAR) Stock Price Down 4.8%

Pharming Group (NASDAQ:PHAR) shares fell 4.8% during mid-day trading on Wednesday . The stock traded as low as $8.03 and last traded at $8.18. 3,319 shares changed hands during trading, a decline of 28% from the average session volume of 4,611 shares. The stock had previously closed at $8.59.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Thursday, September 26th.

Pharming Group Trading Down 8.0 %

The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65. The stock’s 50 day moving average is $7.78 and its 200-day moving average is $8.82. The company has a market capitalization of $532.02 million, a P/E ratio of -49.38 and a beta of 0.14.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The firm had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same quarter in the previous year, the business earned $0.02 EPS. As a group, equities research analysts anticipate that Pharming Group will post -0.15 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.